{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T10:25:43Z","timestamp":1768818343877,"version":"3.49.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>We evaluated the prognostic value of baseline total metabolic tumor volume (TMTV) measured using pretreatment FDG PET for patients with transformation of chronic lymphocytic leukemia (CLL) into diffuse large B-cell lymphoma (DLBCL).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A total of 28 patients with transformation of CLL into DLBCL who had undergone FDG PET before treatment were retrospectively reviewed. Univariate and multivariate analysis of conventional clinicopathologic variables (sex, age, World Health Organization performance status score, International Prognostic Index score, Binet stage, lactate dehydrogenase serum level [LDH], platelet count, presence or not of prior therapies for CLL, the time from CLL to Richter syndrome, Ann Arbor stage, Bulky or not) and metabolic parameters (SUV<jats:sub>max<\/jats:sub>, SUV<jats:sub>mean<\/jats:sub>, TMTV, and total lesion glycolysis) at the time of the transformation of CLL into DLBCL were tested for overall survival (OS).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of the 28 patients, 14 patients (50%) died during the follow-up period. Low platelet count, World Health Organization performance status score &gt;1, high LDH, and high TMTV were found to be significant prognostic factors for OS on univariate analysis. The 5-year estimates of OS were 63% in the low metabolic burden group (TMTV \u22641200 cm<jats:sup>3<\/jats:sup>) and 0% in the high metabolic burden group (TMTV &gt;1200 cm<jats:sup>3<\/jats:sup>). Multivariate analysis revealed that only high LDH was a significant predictor after adjustment for other variables of OS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>TMTV extracted from FDG PET at the time of the transformation of CLL into DLBCL is a predictor of OS.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000002879","type":"journal-article","created":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T19:40:22Z","timestamp":1577216422000},"page":"118-122","source":"Crossref","is-referenced-by-count":19,"title":["Prognostic Value of Baseline Total Metabolic Tumor Volume Measured on FDG PET in Patients With Richter Syndrome"],"prefix":"10.1097","volume":"45","author":[{"given":"Cl\u00e9mence","family":"Pontoizeau","sequence":"first","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Girard","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Habiba","family":"Mesbah","sequence":"additional","affiliation":[{"name":"Medical Information, CLCC Eug\u00e8ne Marquis"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laure-Anne","family":"Haumont","sequence":"additional","affiliation":[{"name":"Medical Information, CLCC Eug\u00e8ne Marquis"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Devillers","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Tempescul","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology, CHRU Brest, Rennes"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Yves","family":"Sala\u00fcn","sequence":"additional","affiliation":[{"name":"Univ Bretagne Occidentale, Department of Nuclear Medicine, CHRU Brest, GETBO Research Unit, Brest"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Lamy","sequence":"additional","affiliation":[{"name":"Univ Rennes, Department of Clinical Hematology, CHU Rennes, MICA Research Unit"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Le Jeune","sequence":"additional","affiliation":[{"name":"Univ Rennes, Department of Nuclear Medicine, CLCC Eug\u00e8ne Marquis, \u201cBehavior and Basal Ganglia\u201d Research Unit"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Palard-Novello","sequence":"additional","affiliation":[{"name":"Univ Rennes, Department of Nuclear Medicine, CLCC Eug\u00e8ne Marquis, Inserm, LTSI\u2013UMR 1099 Research Unit, Rennes, France."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2019,12,24]]},"reference":[{"key":"bib1-20230925","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/bjh.12458","article-title":"Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients","volume":"162","year":"2013","journal-title":"Br J Haematol"},{"key":"bib2-20230925","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","article-title":"Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation","volume":"24","year":"2006","journal-title":"J Clin Oncol"},{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","year":"2011","journal-title":"Blood"},{"key":"bib4-20230925","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2013-11-516229","article-title":"How we treat Richter syndrome","volume":"123","year":"2014","journal-title":"Blood"},{"key":"bib5-20230925","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2005.12.072","article-title":"Intensity of 18Fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma","volume":"23","year":"2005","journal-title":"J Clin Oncol"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1007\/s00259-013-2435-6","article-title":"An international confirmatory study of the prognostic value of early PET\/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and \u0394SUVmax","volume":"40","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib7-20230925","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1166\/jmihi.2016.1910","article-title":"Assessment of Interobserver reproducibility in quantitative [18F]-Fluoro-2-deoxy-glucose positron emission tomography\/computed tomography measurements in non-small cell lung cancer","volume":"6","year":"2016","journal-title":"J Med Imaging Health Inform"},{"key":"bib8-20230925","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00259-009-1297-4","article-title":"FDG PET and PET\/CT: EANM procedure guidelines for tumour PET imaging: version 1.0","volume":"37","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib9-20230925","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00259-014-2783-x","article-title":"Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma","volume":"41","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib10-20230925","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s00259-014-2822-7","article-title":"Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma","volume":"41","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib11-20230925","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00259-018-4173-2","article-title":"Prognostic role of baseline 18F-FDG PET\/CT metabolic parameters in Burkitt lymphoma","volume":"46","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib12-20230925","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high\u2013tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib13-20230925","first-page":"76","article-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tumours","volume":"1","year":"2008","journal-title":"Lyon, France: International Agency for Research on Cancer"},{"key":"bib14-20230925","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the eastern cooperative oncology group","volume":"5","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"bib15-20230925","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","year":"1981","journal-title":"Cancer"},{"key":"bib16-20230925","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","year":"2007","journal-title":"Blood"},{"key":"bib17-20230925","doi-asserted-by":"crossref","first-page":"e0140830","DOI":"10.1371\/journal.pone.0140830","article-title":"Influence of software tool and methodological aspects of Total metabolic tumor volume calculation on baseline [18F] FDG PET to predict survival in Hodgkin lymphoma","volume":"10","year":"2015","journal-title":"PLoS One"},{"key":"bib18-20230925","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00259-014-2705-y","article-title":"Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients","volume":"41","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib19-20230925","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting","volume":"7","year":"1989","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"bib20-20230925","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.3109\/10428194.2015.1099643","article-title":"An 18F-FDG-PET maximum standardized uptake value > 10 represents a novel valid marker for discerning Richter's syndrome","volume":"57","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"bib21-20230925","first-page":"1267","article-title":"Detection of Richter's transformation of chronic lymphocytic leukemia by PET\/CT","volume":"47","year":"2006","journal-title":"J Nucl Med"},{"key":"bib22-20230925","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00277-011-1357-2","article-title":"Clinical significance of metabolic tumor volume by PET\/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement","volume":"91","year":"2012","journal-title":"Ann Hematol"},{"key":"bib23-20230925","first-page":"98","article-title":"Lactic dehydrogenase","volume":"15","year":"1964","journal-title":"Med Sci"},{"key":"bib24-20230925","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejrad.2018.05.014","article-title":"The prognostic value of SUV max measuring on primary lesion and ALN by 18F-FDG PET or PET\/CT in patients with breast cancer","volume":"105","year":"2018","journal-title":"Eur J Radiol"},{"key":"bib25-20230925","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/IGC.0000000000001207","article-title":"Prognostic impact of pretreatment Fluorodeoxyglucose positron emission tomography\/computed tomography SUVmax in patients with locally advanced cervical cancer","volume":"28","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"bib26-20230925","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/JTO.0000000000000185","article-title":"Primary tumor standardized uptake value measured on F18-Fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non\u2013small-cell lung cancer receiving radiotherapy: meta-analysis","volume":"9","year":"2014","journal-title":"J Thorac Oncol"},{"key":"bib27-20230925","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/RLU.0000000000001740","article-title":"Pretreatment primary tumor SUVmax on 18F-FDG PET\/CT images predicts outcomes in patients with salivary gland carcinoma treated with definitive intensity-modulated radiation therapy","volume":"42","year":"2017","journal-title":"Clin Nucl Med"},{"key":"bib28-20230925","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/cncr.21967","article-title":"Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas","volume":"107","year":"2006","journal-title":"Cancer"},{"key":"bib29-20230925","doi-asserted-by":"crossref","first-page":"e2017029","DOI":"10.4084\/mjhid.2017.029","article-title":"FDG-PET scan: a new paradigm for follicular lymphoma management","volume":"9","year":"2017","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"bib30-20230925","doi-asserted-by":"crossref","first-page":"325","DOI":"10.17219\/acem\/31804","article-title":"PET\/CT assessment of follicular lymphoma and high grade B cell lymphoma - good correlation with clinical and histological features at diagnosis","volume":"24","year":"2015","journal-title":"Adv Clin Exp Med"},{"key":"bib31-20230925","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3324\/haematol.12013","article-title":"Investigation of FDG-PET\/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma","volume":"93","year":"2008","journal-title":"Haematologica"},{"key":"bib32-20230925","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdn657","article-title":"The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL)","volume":"20","year":"2009","journal-title":"Ann Oncol"},{"key":"bib33-20230925","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1002\/ijc.26322","article-title":"Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis","volume":"130","year":"2012","journal-title":"Int J Cancer"},{"key":"bib34-20230925","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/RLU.0000000000002284","article-title":"SUV harmonization between different hybrid PET\/CT systems","volume":"43","year":"2018","journal-title":"Clin Nucl Med"},{"key":"bib35-20230925","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1182\/blood-2014-12-616474","article-title":"Utility of baseline 18FDG-PET\/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma","volume":"126","year":"2015","journal-title":"Blood"},{"key":"bib36-20230925","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1182\/blood-2015-07-653386","article-title":"Quantitative FDG-PET: a new biomarker in PMBCL","volume":"126","year":"2015","journal-title":"Blood"},{"key":"bib37-20230925","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1007\/s00259-015-3128-0","article-title":"Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients","volume":"42","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002879","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T06:07:32Z","timestamp":1695622052000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,24]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000002879","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,24]]}}}